Ensysce Biosciences logged a 12.0% change during today's morning session, and is now trading at a price of $0.8 per share. It was a relatively calm morning for the broader market, with the S&P 500 index moving 0.8% and the Nasdaq posted a 2.3% change.
Ensysce Biosciences shares moved -97.7% over the last 52 weeks, with a high of $35.6 and a low of $0.59. During this time, the stock lagged the S&P 500 index by -89.7%. As of January 2022, the company's 50-day average price is $1.23. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. The small-cap Healthcare company has 6 full time employees and is based in La Jolla, CA. Ensysce Biosciences has not offered any dividends in the last year.
The Company Does Not Yet Have Revenues:
|Earnings Per Share||$0.05||-$29.6|
|Free Cash Flow (k)||-$1,247||-$8,242|
|LT Debt to Equity||-0.0||-0.56|
Ensysce Biosciences has negative earnings for the current period, so its trailing twelve month P/E ratio is not meaningful. Its forward P/E isn't meaningful either because its guidance EPS is -6.74.
Ensysce Biosciences Benefits From Positive Market Indicators:
3 analysts are following Ensysce Biosciences and have set target prices ranging from $5.3 to $8 per share. On average, they have given the company a rating of buy. At the current price of $0.8, ENSC is trading -87.36% away from its average analyst target price of $6.33 per share, implying an analyst consensus of strong upside potential for the stock.
The company has a very low short interest since 1.3% of the company's shares are tied to short positions. Institutions own 19.6% of Ensysce Biosciences's shares, while the insider ownership rate stands at 18.78%. The biggest shareholder is HG Vora Capital Management, LLC with a 2% stake in the company worth approximately $98,500.